2009 Annual Saturday

Orlando, FL - ASCO 2009 Annual Meeting: Roy Herbst discusses Abstract 8003 - Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). during a press conference at the American Society for Clinical Oncology Annual Meeting here today, Saturday May 30, 2009. Over 25,000 physicians, researchers and healthcare professionals from over 80 countries are attending the meeting which is being held at the Orange County Convention center and features the latest cancer research in the areas of basic and clinical science. Date: Saturday May 30, 2009 Photo by © ASCO/Todd Buchanan 2009 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.